4 - Tempus AI, Inc. (0001717115) (Issuer)

4 - Tempus AI, Inc. (0001717115) (Issuer)

4 - Tempus AI, Inc. (0001717115) (Issuer)

4 - Tempus AI, Inc. (0001717115) (Issuer)

4 - Tempus AI, Inc. (0001717115) (Reporting)

4 - Tempus AI, Inc. (0001717115) (Issuer)

4 - Tempus AI, Inc. (0001717115) (Issuer)

4 - Tempus AI, Inc. (0001717115) (Issuer)

3 - Tempus AI, Inc. (0001717115) (Issuer)

4 - Tempus AI, Inc. (0001717115) (Issuer)

Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the collaboration with Flatiron Health, a leading healthtech company dedicated to expanding the possibilities of point of care solutions in oncology, to integrate its comprehensive genomic testing directly into Flatiron's cloud-based Electronic Medical Record (EMR) platform, OncoEMR® through the Molecular Profiling Integration (MPI). This integration will provide oncologists with seamless access to Tempus' suite of testing options, enhancing their ability to deliver personalized cancer care. Flatiron's MPI—a two-way integration between laboratories

Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced publication of its study, "Actionable structural variant detection via RNA-NGS and DNA-NGS in patients with advanced non-small cell lung cancer," in JAMA Network Open. Tempus recently conducted a retrospective study of more than 5,500 patients with advanced non-small cell lung cancer (NSCLC) and found that concurrent RNA- and DNA-based next-generation sequencing (NGS) led to the detection of more actionable structural variants compared to DNA sequencing alone. Specifically, 8.8% of patients had at least one actionable variant – ALK, RET, ROS1, or NTR

Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced nine abstracts were accepted for presentation at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting, which convenes in Houston, Texas, from November 6-10, 2024. "Presenting our latest research is a vital opportunity to showcase the advancements Tempus is making in harnessing the power of data and AI to drive immunotherapy innovation," said Ezra Cohen, MD, Chief Medical Officer of Oncology at Tempus. "We are committed to working with the oncology community to share insights that can accelerate the development of more effective, perso

IPS test validation study data will be unveiled at the 2024 SITC Annual Meeting Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the clinical launch of its Immune Profile Score (IPS) algorithmic test. IPS, which is now available for clinicians to order, is a multimodal biomarker that can be used as a prognostic indicator for adult patients with stage IV and metastatic pan-solid tumors who are already considered candidates for immune checkpoint inhibitor (ICI)-based therapy. Tempus is presenting the results of its validation study at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter that ended September 30, 2024. The company also announced that it has entered into an agreement to acquire Ambry Genetics, a leader in genetic testing that aims to improve health by understanding the relationship between genetics and disease. Revenue increased 33.0% year-over-year to $180.9 million in the third quarter of 2024 Data and services revenue growth accelerated to 64.4% year-over-year Genomics unit growth accelerated to 23.9% annually with rising average revenue per clinical test Net Loss of $(75.8 mi

Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the third quarter on Monday, November 4, 2024. The company will hold the third quarter 2024 earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The company's conference call that was previously scheduled for November 7, 2024 has been canceled. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the

Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the third quarter on Thursday, November 7, 2024. The company will hold the third quarter 2024 earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 7177136 Domestic Dial-in Number: (800) 715-9871 International Dial-in

Avacta Group plc ("Avacta" or "the Group" or "the Company") Avacta and Tempus Enter Strategic Collaboration to Advance AI-Driven Drug Development in Oncology LONDON – Oct. 21, 2024 – Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announces the initiation of an artificial intelligence (AI)-focused collaboration with Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of artificial intelligence to advance precision medicine and patient care. The strategic collaboration will provide Avacta access to Tempus' multimodal datasets comprising

Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announces an expansion to its collaboration with Takeda (NYSE:TAK) that takes a data-first approach to research and development, with the aim of enhancing Takeda's oncology research and development efforts. After an initial collaboration that leveraged Tempus' de-identified multimodal datasets, this new agreement will expand upon that work. Takeda will combine Tempus' multimodal real-world datasets and Tempus' biological modeling capabilities to advance Takeda's pipeline of cancer therapeutics, which includes antibody-drug conjugates (ADCs), small molecules, b

Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced four abstracts were accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2024, which convenes in Barcelona, Spain, from September 13-17, 2024. "ESMO provides a great platform to share our recent research and advancements with the global oncology community, foster further collaboration, and drive forward the mission of improving patient outcomes," said Ezra Cohen, MD, Chief Medical Officer of Oncology at Tempus. "At Tempus, we are committed to leveraging AI and data to transform cancer care and research, and this is a

8-K - Tempus AI, Inc. (0001717115) (Filer)

SCHEDULE 13G - Tempus AI, Inc. (0001717115) (Subject)

10-Q - Tempus AI, Inc. (0001717115) (Filer)

8-K - Tempus AI, Inc. (0001717115) (Filer)

8-K - Tempus AI, Inc. (0001717115) (Filer)

8-K - Tempus AI, Inc. (0001717115) (Filer)

10-Q - Tempus AI, Inc. (0001717115) (Filer)

8-K - Tempus AI, Inc. (0001717115) (Filer)

S-8 - Tempus AI, Inc. (0001717115) (Filer)

8-K - Tempus AI, Inc. (0001717115) (Filer)

These eleven mid-cap stocks were the best performers in the last week. Are they in your portfolio? Virtu Financial, Inc. (NASDAQ:VIRT) shares jumped 30.04% after reporting better-than-expected Q2 financial results. V.F. Corporation (NYSE:VFC) stock upped 22.38% after the company announced it entered into a Stock and Asset Purchase Agreement to sell its Supreme brand to EssilorLuxottica (OTC: ESLOF) for $1.5 billion in cash. Several analysts raised their price forecasts on VFC. New Fortress Energy Inc. (NASDAQ:NFE) shares grew 20.19% after the company announced that it achieved First LNG for its initial Fast LNG asset located offshore Altamira, Mexico. Riot Platforms Inc (NASDAQ:

U.S. stocks were mostly higher, with the Dow Jones index gaining around 550 points on Tuesday. Shares of UnitedHealth Group Incorporated (NYSE:UNH) rose sharply during Tuesday's session following a second-quarter earnings beat. The company reported adjusted EPS of $6.80, up from $6.14 a year ago, beating the consensus of $6.66, according to data from Benzinga Pro. UnitedHealth’s revenues increased nearly $6 billion (+6.4% Y/Y) to $98.86 billion, beating the consensus of $98.34 billion, led by expansion in people served domestically at Optum and UnitedHealthcare. UnitedHealth Group shares gained 5.7% to $544.96 on Tuesday. Here are some other big stocks recording gains in today’s

Available Today for Life Science Research Use OnlyTempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced that its multimodal immune profile score (IPS) algorithmic test is now available for research use only (RUO). IPS is the first offering of a larger immunotherapy-based portfolio being developed at Tempus to bring next-generation algorithmic diagnostics to the immuno-oncology space. Additionally, Tempus is collaborating with other partners, like Cleveland Clinic, to bring additional immunotherapy-focused algorithmic tests to this growing portfolio, leveraging clinical, laboratory, genomic, and transcriptomic data to identify patients that

In a recent development, Flagship Pioneering, the venture capital firm known for backing Moderna (NASDAQ:MRNA) has successfully secured a whopping $3.6 billion in funding. What Happened: Flagship Pioneering has raised $2.6 billion for its eighth fund and an additional $1 billion for parallel funds. These parallel funds will be invested in specific sectors such as diagnostics or therapeutics. The venture firm is also planning to raise more funds for its eighth fund later this year. The funds are intended to launch a series of new biotech companies that will harness the power of generative artificial intelligence for drug discovery, The Financial Times reported on Wednesday. Noubar Afeya

Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, has reached a research milestone of over 500 research publications. In the last eight years, Tempus has invested in rigorous scientific research to validate its diagnostic offerings, while also working with biopharma and academic collaborators to publish research supported by the company's multimodal data library. This research milestone includes published and/or acknowledged work, comprised of:143 peer-reviewed articles, of which 106 were Tempus-authored;291 poster presentations based on clinical and research data presented at major scientific conferences; and31 oral presentations at scientific meeting

William Blair initiated coverage on Tempus AI, Inc (NASDAQ:TEM), citing the company’s ‘differentiated approach and business model.’ Tempus AI is a healthcare technology company that utilizes artificial intelligence technology to collect and analyze molecular, clinical, and genomic data. It collects clinical and genomic databases from academic medical centers and community-based hospitals. Related: Tempus Could Gain Share In AI Health Care Market Poised To Grow By Over 30%. In June, the company launched an IPO priced at $37 per share via selling 11.1 million shares, with gross proceeds of around $410.7 million. William Blair says the Outperform rating is based on “What we belie

B of A Securities analyst Michael Ryskin initiates coverage on Tempus AI (NASDAQ:TEM) with a Buy rating and announces Price Target of $41.

Tempus AI Inc (NASDAQ:TEM) announced last week it was granted advanced diagnostic laboratory test status for its next-generation sequencing assay. These analysts provide their initial takeaways from the stock. BofA Securities On Tempus Analyst Michael Ryskin initiated coverage with a Buy rating and price target of $41. Providing AI-enabled precision medicine, Tempus brings "the power of advanced technology to healthcare and diagnostics" and delivers personalized therapy decisions, Ryskin said in his initiation note. "This platform is being monetized as a diagnostic offering and by leveraging the power of the database to Biopharma partners," he added. Tempus serves a large tota

William Blair analyst Andrew Brackmann initiates coverage on Tempus AI (NASDAQ:TEM) with a Outperform rating.

JP Morgan analyst Rachel Vatnsdal initiates coverage on Tempus AI (NASDAQ:TEM) with a Overweight rating and announces Price Target of $42.